Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia

Thrombosis Research

Volumn 124, Issue 4, 2009, Pages 427-432

  Heylen, Evelien ^a   Miljic, Predrag ^b   Willemse, Johan ^a   Djordjevic, Valentina ^c   Radojkovic, Dragica ^c   Colovic, Milica ^b   Elezovic, Ivo ^b   Hendriks, Dirk ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c INSTITUTE OF MOLECULAR GENETICS AND GENETIC ENGINEERING   (Serbia)

Author keywords

Hereditary thrombophilia; Pregnancy loss; Procarboxypeptidase U; ProCPU polymorphism; TAFI; Thrombotic risk

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMOGRAPHY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTHENOGENESIS; PRIORITY JOURNAL; THROMBOPHILIA; VEIN THROMBOSIS;

ADULT; CARBOXYPEPTIDASE U; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION; POLYMORPHISM, GENETIC; PROTHROMBIN; THROMBOPHILIA; THROMBOSIS;

EID: 69249216811     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.01.005     Document Type: Article

References (35)

1. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
2. Rosendorff A., and Dorfman D. Activated protein C resistance and factor V Leiden: a review. Arch Pathol Lab Med 131 (2007) 866-871
3. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
4. Lensen R.P., Bertina R.M., de Ronde H., Vandenbroucke J.P., and Rosendaal F.R. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 83 (2000) 817-821
5. Zoller B., Holm J., Svensson P.J., and Dahlback B. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein s deficiency. Thromb Haemost 75 (1996) 270-274
6. Martinelli I., Bottasso B., Duca F., Faioni E., and Manucci P.M. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost 75 (1996) 703-705
7. Coppens M., Folkeringa N., Teune M.J., Hamulyak K., van der Meer J., Prins M.H., et al. Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. J Thromb Haemost 5 (2007) 1444-1448
8. Gouin-Thibault I., Arkam R., Nassiri S., de la Tourette A., Conard J., Horellou M.H., et al. Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation. Thromb Res 107 (2002) 7-11
9. Hendriks D., Scharpé S., van Sande M., and Lommaert M.P. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 27 (1989) 277-285
10. Bajzar L., Manuel R., and Nesheim M.E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 270 (1995) 14477-14484
11. Hendriks D.F., and Willemse J.L. Discovery of thrombin activatable fibrinolysis inhibitor (TAFI). J Thromb Haemost 4 (2006) 261-262
12. Wang W., Boffa M.B., Bajzar L., Walker J.B., and Nesheim M.E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 273 (1998) 27176-27181
13. Mosnier L.O., and Bouma B.N. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 26 (2006) 2445-2453
14. Bazjar L., Morser J., and Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271 (1996) 16603-16608
15. Willemse J.L., and Hendriks D.F. A role for procarboxypeptidase U (TAFI) in thrombosis. Front Biosci 12 (2007) 1973-1987
16. Bajzar L., Kalafatis M., Simioni P., and Tracy P.B. An antifibrinolytic mechanism describint the prothrombotic effect associated woth factor V Leiden. J Biol Chem 271 (1996) 22949-22952
17. Parker A.C., Mundada L.V., Schmair A.H., and Fay W.P. Factor V Leiden inhibitis fibrinolysis in vivo. Circulation 110 (2004) 3594-3598
18. Schneider M., Boffa M., Stewart R., Rahman M., Koschinsky M., and Nesheim M. Two naturally occuring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 277 (2002) 1021-1030
19. Knecht W., Willemse J., Stenhamre H., Andersson M., Berntsson P., Furebring C., et al. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demostrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis. FEBS J 273 (2006) 778-792
20. Folkeringa N., Coppens M., Veeger N.J.G., Bom V.J., Middeldorp S., Hamulyak K., et al. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activable fibrinolysis inhibitor (TAFI) levels. Thromb Haemost 100 (2008) 38-44
21. Libourel E.J., Bank I., Meinardi J.R., Balje -Volkers C.P., Hamulyak K., Middeldorp S., et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 87 (2002) 1068-1073
22. van Tilburg N.H., Rosendaal F.R., and Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95 (2000) 2855-2859
23. Willemse J.L., Leurs J.R., and Hendriks D.F. Fast kinetic assay for the determination of procarboxypeptidase U (TAFI) in human plasma. J Thromb Haemost 3 (2005) 2353-2355
24. Willemse J.L., Matus V., Heylen E., Mezzano D., and Hendriks D.F. Influence of the Thr325Ile polymorphism on procarboxypeptidase U (TAFI) activity-based assays. J Thromb Haemost 5 (2007) 872-875
25. Cushman M., Psaty B.M., Macy E., Bovill E.G., Cornell E.S., Kuller L.H., et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol 16 (1996) 1163-1169
26. Zorio E., Castello R., Falco C., Espana F., Osa A., Almenar L., et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 122 (2003) 958-965
27. Woolf B. On estimating the relation between blood group and disease. Am J Hum Genet 19 (1955) 251-253
28. Brouwers G.J., Vos H.L., Leebeek F.W.G., Bulk S., Schneider M., Boffa M., et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 98 (2001) 1992-1993
29. Antovic J.P., and Blombäck M. Thrombin-activable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation. Thromb Res 106 (2002) 59-62
30. Meijers J.C.M., Oudijk E.J.D., Mosnier L.O., Bos R., Bouma B.N., Nieuwenhuis H.K., et al. Reduced activity of TAFI (thrombin-activable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 108 (2000) 518-523
31. Heit J.A. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3 (2005) 1611-1617
32. Ridker P.M., Miletich J.P., Stampfer M.J., Goldhaber S.Z., Lindpaintner K., and Hennekens C.H. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 92 (1995) 2800-2802
33. Simioni P., Prandoni P., Lensing A.W.A., Manfrin D., Tormene D., Gavasso S., et al. Risk of subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep vein thrombosis. Blood 96 (2000) 3329-3333
34. Eichinger S., Schonauer V., Weltermann A., Minar E., Bialonczyk C., Hirschl M., et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 103 (2004) 3773-3776
35. Morange P., Henry M., Frére C., Juhan-Vague I., and (HIFMECH study group). Thr325Ile polymorphism in the TAFI gene does not influence the risk of myocardial infarction. Blood 99 (2002) 1878-1879